Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Paris and Tarrytown, N.Y. - January 8, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. will accelerate and expand investment for the clinical development of the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.
http://ift.tt/2qHO9x6
No comments:
Post a Comment